| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1398667 | European Journal of Medicinal Chemistry | 2016 | 12 Pages |
•A new series of TRH analogues was synthesized.•Peptide 7k showed 925-fold selectivity towards mTRH-R2 receptor in the IP-1 assay.•Peptide 7k showed 272-fold selectivity towards mTRH-R2 receptor in the FLIPR assay.•Peptide 7k decreased the sleeping time by >76% in a PB-induced assay.
Thyrotropin-releasing hormone (TRH) analogues bearing halogen groups (Cl, Br and I) at the C-2 and/or C-5 position, and the alkyl group (CH3, C2H5, C3H7, CH2C6H5) at the N-1 position of the imidazole ring of the central histidine residue were synthesized and evaluated for the receptor binding, calcium mobilization (FLIPR), and IP-1 assay at the HEK mTRHR1 and HEK mTRHR2 expressing cell lines. The most promising analogue 7k showed 925-fold selectivity for HEK mTRH-R2 receptor subtype in the IP-1 assay, 272-fold selectivity for HEK mTRH-R2 receptor subtype in the FLIPR assay, and 21-fold receptor binding specificity at HEK TRH-R2 receptor subtype. The peptide 7k was evaluated in vitro in a brain membrane competitive binding assay, and for stability analysis in the presence of TRH-DE, in vivo. The analogue 7k showed decrease in the sleeping time by more than 76% in a pentobarbital-induced sleeping assay, and showed comparatively less elevation in the TSH level in the blood, in vivo. The computational homology modeling of TRH-R1 and TRH-R2 and docking study with the most potent peptide 7k provide impetus to design CNS specific TRH analogues.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
